Rosetta (mile)stones

Rosetta Capital Ltd.'s latest secondary equity acquisition fits into the firm's wheelhouse because the deal includes clinical-stage companies with upcoming catalysts.

Last week, the London life sciences venture firm acquired undisclosed stakes in 20 companies from the corporate VC arm of an undisclosed "major pharmaceutical company."...